Research And Development

As Jeff Yoshimi, PhD, wrote his book about how video games could improve scientific literacy on cancer and generate ideas that could eventually lead to treatments, he proposed this title to his mother: “Curing Disease Using Video Games.”

A pharmaceutical company and a biotechnology firm have announced a development and license agreement for an investigational proprietary biologic combination therapy to treat amyotrophic lateral sclerosis.

A United Kingdom-based biotech company has announced a global licensing agreement with a California pharma firm to research and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

JCR Pharmaceuticals Co. has entered into an agreement with AstraZeneca’s Rare Disease division, Alexion, to develop a novel therapeutic molecule for the treatment of neurodegenerative disease.

Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.

Santen, Massachusetts Eye and Ear and Ulster University have formed a research initiative to investigate and develop novel therapies for the treatment of glaucoma, according to a press release.

NovaBay Pharmaceuticals reported a second quarter net loss of $2.5 million, or $0.14 per share, compared with a net loss of $1.6 million, or $0.09 per share, in the same period of 2018, according to a press release.

Harrow Health reported total revenues of $13.5 million in the second quarter of 2019 compared with $10.4 million in the same period a year ago, according to a press release.

Eyenovia reported a second quarter net loss of $5.3 million, or $0.44 per share, compared with a net loss of $3.3 million, or, $0.33 per share, at the same time last year, according to a press release.

Kala Pharmaceuticals reported a net loss of $23.8 million, or $0.70 per share, for the second quarter of 2019 compared with a net loss of $14.6 million, or $0.60 per share, for the same period a year ago, according to a press release.